ImmuPharma的股票尽管有1 658万英镑的市场上限和有前途的Lupus治疗,却下跌了11.7%。 ImmuPharma's stock drops 11.7% despite its £16.58 million market cap and promising Lupus treatment.

ImmuPharma是一家生物制药公司,开发自发免疫疾病治疗方法,星期四库存量下降了11.7%,每股3.80便士。 ImmuPharma, a biopharmaceutical company developing treatments for autoimmune diseases, saw its stock fall 11.7% on Thursday, closing at 3.80 pence per share. 该公司的市场上限为1 658万英镑。 The company's market cap is £16.58 million. 其主导方案P140(LupuzorTM)针对Lupus和其他具有独特自主机制的自发性疾病。 Its lead program, P140 (Lupuzor™), targets Lupus and other autoimmune diseases with a unique autophagy mechanism.